NASDAQ Warns It Could Delist Cyclacel
At issue is the company’s failure to comply with NASDAQ’s $10 million shareholder equity minimum requirement.
Cyclacel said it will request a hearing with the exchange in order to address these concerns.
CYCC shares dropped 12 cents to close at $1.24 in trading today. Despite that, the stock is above the midpoint in its one-year trading range.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted in: News